Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.05 | N/A | +3.33% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.05 | N/A | +3.33% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding the company's future. They emphasized their focus on pipeline advancements despite current market challenges.
Management highlighted ongoing commitment to innovation and pipeline development.
They acknowledged challenges in the market but expressed confidence in long-term growth.
Bristol Myers Squibb's earnings report showed a positive surprise in EPS, which reflects better-than-expected performance in that area. However, the stock reacted negatively, declining by 0.6%. This may indicate investor concerns about other aspects of the business, particularly since no revenue figures or guidance were provided.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERIPRISE FINL INC
Apr 24, 2023